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INTERLEUKIN-6 (IL-6) and soluble interleukin-6 re-
ceptor (sIL-6R) were detected in supernatants of
cultures of B chronic lymphatic leukaemia (CLL)
lymphocytes. Phorbol-12-myristate 13 acetate
(PMA) caused a decrease in the levels of IL-6 in 14
out of 16 cultures and an increase in levels of sIL-
6Rin all 15 cases. The effect of pokeweed mitogen
(PWM) was variable and not signi￿ cant. The levels
of IL-6 were below the detection limit (60 pg/ml)
in sera of 13 CLL patients whereas sIL-6R was
detected (13 ng/ml to 97 ng/ml) in the 13 sera. IL-
6 was not detected in cultures of unstimulated or
stimulated with PMA or PWM normal human B
cells. Levels of sIL-6R were minimal in cultures of
normal B lymphocytes and were increased in
PMA stimulated cultures. The results are consis-
tent with the view that B-CLL cells produce spon-
taneously IL-6 which could act in an autocrine
fashion to cause shedding of surface IL-6R and
account for the correlation found between serum
levels of sIL-6R and B-CLL lymphocyte numbers.
The fall in levels of IL-6 in PMA stimulated CLL
cultures might express masking or degradation of
IL-6 after combination with the receptor.
Key words: B lymphocytes, CLL, IL-6, PMA, PWM,
sIL-6R.
Introduction
Interleukin-6 (IL-6) is a pleiotropic cytokine
produced by adult T1 and B 2 lymphocytes, fetal
mononuclear cells,3 macrophages,4 ￿broblasts,5
endothelial cells and chondrocytes.5 IL-6 is
involved in growth of myeloma cells,6 induction
of IL-2 and IL-2 receptor expression,7 matura-
tion of megakaryocytes,8 and production of
acute protein in liver cells.5 IL-6 was reported
to induce immunoglobulin secretion by acti-
vated B cells. It acts on various cells by binding
to IL-6 speci￿c receptor and by activation of the
associated signal transducer gp130.9 Various
soluble cytokine receptors were recently identi-
￿ed: IL-6,10 IFN-c,11 TNF-a 12 and IL-1a.13 Anti-
bodies to human IL-6 receptor (IL-6R) were
prepared,14 thus enabling the study of the
expression of IL-6R on the cell surface and the
levels of soluble IL-6R(sIL-6R) in human sera.
B-cell chronic lymphatic leukaemia (B-CLL) is
a malignant clonal proliferation of apparently
mature CD5 B lymphocytes. The number of
pathological B cells varies from a few thousand
to more than one hundred thousand per 1 ml.
The present study was intended to determine
IL-6 and sIL-6R levels in supernatants of short-
term cultures of CLLB lymphocytes and normal
peripheral blood human B lymphocytes (NB) in
non-stimulated cultures and culture stimulated
with either pokeweed mitogen (PWM) or phor-
bol 12-myristate 13 acetate (PMA). Concomit-
antly the levels of IL-6 and sIL-6R in sera of CLL
patients were determined.
Materials and Methods
Samples
Sterilized heparinized peripheral blood was
obtained after consent from untreated B-CLL
patients attending the outpatient haematology
clinic at Meir General Hospital, Kfar-Saba, Israel
and from normal volunteers. Freshly obtained
or cryopreserved lymphocytes were studied.
The stage of B-CLLvaried from 0 to 3 according
to Rai classi￿cation.15
Separation of lymphocytes
Peripheral blood mononuclear cells (PBMC)
were separated from peripheral blood by Ficoll-
hypaque density centrifugation.16
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PBMC from healthy subjects were treated with
Dynabeads M-450 coated with anti-CD19 anti-
bodies (Dynal AS, Oslo, Norway), as recom-
mended by the manufacturers. The CD19
cells were released from the beads by 24 h
incubation at 378 C and removed by the Dynal
Magnetic Concentrator. The B-cell percentage
was determined by staining the cells with
￿uoresceinated antitotal Ig.
Negative selection of B cells
PBMC were incubated on plastic plates for 1 h
at 378 C to remove the adherent cells (mono-
cytes). The nonadherent cells were treated
with Dynabeads coated with anti-CD2 anti-
bodies (Dynal AS) as recommended by the
manufacturers. Non-adherent cells were re-
moved and consisted of highly puri￿ed B
cells.
Culture of B-CLL or normal B
lymphocytes
B-CLL lymphocytes were used either as PBMC
after Ficoll-hypaque separation or as puri￿ed B
cells obtained after negative selection. Highly
puri￿ed normal B lymphocytes were obtained
after positive selection. The cells were cultured
in 24-well tissue culture dishes (Nunc, Den-
mark) at a density of 5 3 106 cells/ml per well
in RPMI-1640 medium supplemented with de-
complemented pooled human serum, 10 mM
Hepes, 1%glutamine and an antibiotic± antimi-
totic mixture (CM: complete medium). They
were incubated at 378 C in a humid atmosphere
and 5%CO2 for a period of 3± 7 days. The cells
were cultured either in CM alone or in the
presence of 10 mg/ml PWM or 10 ng/ml PMA.
Subsequently, the cells were spun and the
supernatants were collected and stored at
708 C until examination for IL-6 and sIL-6R
secretion.
Cell surface markers
The determination of cell surface markers was
done as described previously17 using anti-CD19
and anti-CD3 monoclonal antibodies (Dakopatts,
Denmark) and polyclonal antitotal Ig. The sec-
ond antibody was FITC conjugated rabbit anti-
mouse immunoglobulin (Dakopatts, Denmark).
The number of positively stained cells was
counted either by FACS 440 (Becton-Dickin-
son, CA, USA) or under ￿uorescent epi-micro-
scope.
Determination of sIL-6R
The determination of sIL-6Rlevels in sera and in
supernatants from B-CLL and normal B lympho-
cyte cultures was done by ELISA as described
previously.14 Microtitre plates (Dynatech Lab.,
Alexandria, Virginia, USA) or Nunc immuno-
plates were coated with anti-IL-6R monoclonal
antibodies (immunoglobulin fraction, 120 ml
well, 20 mg ml in PBS) and kept overnight at
48 C. The plates were washed in PBS with BSA
(0.5% ) and Tween-20 (0.05% ) (blocking solu-
tion) and were incubated in the same blocking
solution for at least 2 h at 378 C. The samples
were diluted in the blocking solution containing
also 0.65 M NaCl and 0.1% NP40 and were
added to the cells (100 ml well) and incubated
for 4 h at 378 C. The plates were washed three
times with PBS containing Tween-20 (0.05% )
followed by addition of rabbit anti-sIL-6R serum
(1:1000, 100 ml well) and kept overnight at
48 C. The plates were washed three times and a
conjugate of goat-antirabbit-immunoglobulin-
horseradish-peroxidase (HRP , Bio-Makor, Israel),
100 ml well was added at a dilution of 1:2000
and maintained for 2 h at room temperature.
The plates were washed four times and the
colour was developed by ABTS (2,29 -azino-bis-
3-ethylbenzthiazoline-6-sulphonic acid, Sigma,
USA) with H 2O2 as substrate. The plates were
read by an automatic ELISAreader.
Determination of IL-6 levels
The ELISA was performed as described above
for sIL-6R. Monoclonal anti-IL-6 antibody 34-118
was used for coating the microtitre plates and
an af￿nity puri￿ed anti-IL-6 (100 ng ml) was
used for detection of IL-6.
Monoclonal anti-sIL-6R antibodies
MoAb to sIL-6R were prepared as reported
previously.14 Monoclonal antibody number
17.66 gave the best results for ELISA and was
used in all the experiments.
Statistical analysis
Results are expressed as means SD. The
Student’s t-test was used to determine the
statistical signi￿cance of the results.
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Levels of IL-6 and sIL-6R in
supernatants of 15 cultures of B-CLL
lymphocytes
The percentage of B cells at the onset of
cultures varied from 82%to 90%and of CD3
cells from 7%to 18% . The cells were cultured
for 3± 7 days. In the supernatants from control
(unstimulated) cultures the levels of IL-6 varied
from 0 25 ng ml to 33 7 ng ml (Table 1).
Stimulating the cells with PMA decreased sig-
ni￿cantly the levels of IL-6 in 12 out of 15
cases (p 0.0044), induced no change in two
cases and increased the IL-6 level in one case
(T able 1). The levels of sIL-6R were increased
in the presence of PMA in all 15 cases
(p 0.0003; Table 1). The effect of PWM on
IL-6 levels was variable and statistically not
signi￿cant: decrease in seven out of 15 super-
natants, increase in three supernatants and no
change in ￿ve supernatants (T ables 1 and 2). In
six cases, the levels of IL-6 (Fig. 1) and of sIL-
6R (Fig. 2) in unstimulated or cultures stimu-
lated with either PMA or PWM, were compared
after 3 and 7 days cultures. The levels of IL-6
did not change markedly in PWM or PMA
stimulated cells by comparison with control
unstimulated cultures. The levels of sIL-6R did
not change markedly in PWM stimulated cul-
tures by comparison with unstimulated cultures
whereas PMA increased signi￿cantly the sIL-6R
levels in ￿ve cultures (p 0.01) and decreased
in one supernatant.
Table 1. IL-6 and sIL-6R levels in supernatants of cultures of B-CLL B lymphocytesa
Patient no. Days in culture Control culturesb (ng/ml) PMA culturesc (ng/ml) PWM culturesd
IL-6 sIL-6R IL-6 sIL-6R IL-6 sIL-6R
1 3 33.7 0.31 5.9 0.46 29.3 0.18
2 5 21.8 0.22 1.6 0.82 8.3 0.20
3 5 6.7 0.06 2.6 0.49 9.8 0.1
4 5 0.7 0.23 0.25 1.8 0.4 0.47
5 6 22.9 0.06 7.64 0.22 18.6 0.22
6 3 0.25 1.05 2.84 1.24 33.44 0.75
7 3 1.39 0.16 0.25 0.40 1.48 0.29
8 5 6.93 0.21 1.86 0.34 6.22 0.31
9 5 20.44 1.13 13.81 1.63 27.91 0.96
10 5 1.54 0.29 0.25 1.86 1.52 0.30
11 5 11.7 0.06 0.40 1.19 6.78 0.02
12 5 13.4 0.14 1.47 1.23 6.88 0.21
13 5 11.5 0.24 1.19 1.27 8.16 0.42
14 5 0.25 0.06 0.25 0.48 0.25 0.27
15 3 0.25 0.17 0.25 0.46 0.25 0.27
Summary
Cellsa Control culturesb (ng/mle) PMA culturesc (ng/mle) PWM culturesd (mg/mle)
IL-6 sIL-6R IL-6 sIL-6R IL-6 sIL-6R
B-CLL 10.2 10.4 0.29 0.33 2.7 3.8f 0.92 0.56f 10.6 11.27 0.33 0.24
NB 0 0.06 0.005 0 0.52 0.31 0 0.11 0.13
aThe cells were cultured (5 3 106 ml) for 3 to 6 days.
bThe cells were cultured in complete medium alone.
cPMA (10 ng ml) or d PWM (10 mg ml) were added to the culture. The level of sIL-6R in the medium was 0 45 ng ml because of the presence
of normal human serum and this amount was subtracted from the values obtained. emean SD; f p , 0.01; B-CLL: 15 cases; NB: 5 cases.
Table 2. Effect of puri® cation of B-CLL B cells stimulated with PMA or PWM on the
levels of IL-6 and sIL-6R in supernatants of 5-day culturesa
Case Mitogen PBMC Puri® ed B cells
no. % of IL-6 sIL-6R % of IL-6 sIL-6R
B T (ng/ml) (ng/ml) B T (ng/ml) (ng/ml)
1 Control 82 18 9.79 0.15 93 3.5 8.53 0.31
PWM 15.76 0.44 9.28 0.47
PMA 5.55 0.57 3.14 0.71
2 Control 85 7 3.18 0.28 90 0 4.14 0.31
PWM 5.99 0.24 4.72 0.72
PMA 1.46 1.39 1.42 0.26
3 Control 90 12 9.02 0.16 99 3 2.7 0.31
PWM 9.67 0.37 2.4 0.12
PMA 3.89 0.65 0.89 0.78
aSee Table 1 for details.
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IL-6 and sIL-6R by B lymphocytesKinetic studies of IL-6 and sIL-6R secretion
were done in cultures of one B-CLLsubject (Fig.
3). Increase of IL-6 secretion was detected after
24 h with highest levels on the second day in
unstimulated cultures. In the PMA stimulated
culture the levels of IL-6 rose to a lesser extent
than in the control (Fig. 3). A slight increase in
the levels of sIL-6R was found already after
30 min of stimulation with PMA (Fig. 3) reach-
ing a peak after 5 days. Low levels of sIL-6R
were detected in the unstimulated culture after
2 h and decreased after 24 h of culture.
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FIG. 1. The levels of IL-6 in supernatants from six B-CLL
lymphocyte cultures after 3 and 7 days. The cells were
either unstimulated (control) or stimulated with PMA
(10 ng/ml) or PWM (10 mg/ml).
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FIG. 2. The levels of sIL-6R in supernatants from six B-CLL
lymphocyte cultures after 3 and 7 days. The cells were
either unstimulated (control) or stimulated with PMA
(10 ng/ml) or PWM (10 mg/ml).
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I. Drucker et al.In three B-CLL patients the B cells were
further puri￿ed by negative selection with CD2
coated beads and the percentage of B cells
raised to 93% , 90% and 99% by comparison
with 82% , 85%and 90%respectively in the non-
enriched samples. The percentage of CD3 posi-
tive cells was 3.5% , 0%and 3%in the B puri￿ed
samples versus 18% , 7%and 10%respectively in
the non-enriched samples (Table 2). Puri￿ed B-
CLL B cells and non-enriched PBMC were
cultured for 5 days either in presence or
absence of PMA or PWM (Table 2). Puri￿ed B
cells paralleled the non-puri￿ed lymphocytes so
far as levels of IL-6 and sIL-6R. The IL-6 levels
decreased in all three puri￿ed B cultures stimu-
lated with PMA(T able 2).
Levels of IL-6 and sIL-6R in
supernatants of normal B
lymphocytes cultures
IL-6 was not detectable in 5-day cultures of
unstimulated, PMA or PWM stimulated normal
Bcells. Only limit levels of sIL-6Rwere found in
unstimulated or PWM stimulated cultures. In
the presence of PMA, the sIL-6R levels increase
to 0 52 0 31 ng ml (T able 1).
IL-6 and sIL-6R levels in sera of B-CLL
patients
The levels of IL-6 were below detection limits
(, 60 pg ml). In 13 sera of B-CLL patients the
levels of sIL-6R were within the range of
13 ng ml to 97 ng ml: in eight cases the levels
were above 40 ng ml. Values of sIL-6R in 200
normal control sera varied between 20 ng ml to
40 ng ml as reported.19 There was a good
correlation between the number of B-CLL lym-
phocytes in the peripheral blood and the levels
of sIL-6R in the sera: in sera of three patients
with lymphocyte counts of 60000 cells ml
or more, the levels of sIL-6R were
74 ng ml 25 ng ml whereas when the counts
were below 60000 the mean levels were
33 4 ng ml 14 ng ml (seven patients). The
difference between the two groups was signi￿-
cant at p 0 01.
Discussion
IL-6 is a cytokine controlling later stages of B
cell maturation and Ig production. It has been
found in supernatants from cultures of freshly
isolated B cells from hypergammaglobulinaemic
patients. Rickmann et al.20 prepared antibodies
against IL-6 which suppressed spontaneous and
Staphylococcus aureus Cowan 1 or IL-2 in-
duced production in vitro.
We found IL-6 and sIL-6R in the supernatants
of unstimulated B-CLL B cell cultures so cor-
roberating the ￿ndings of Biondi et al.21 that B-
CLL lymphocytes produce and secrete IL-6 in
vitro in the absence of speci￿c stimulation. IL-6
was expressed on the membrane of some but
not all B-CLL B cells, which were CD14 or
CD14 but always CD5 .
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FIG. 3. A kinetic study of IL-6 and sIL-6R secretion from one case of B-CLL lymphocytes unstimulated or stimulated with
PMA (10 mg/ml).
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IL-6 and sIL-6R by B lymphocytesIn the presence of PMA, B-CLLB lymphocytes
released less IL-6 in the supernatants of cultures
already after 2 h of incubation, whereas sIL-6R
levels increased markedly by comparison with
unstimulated controls. A similar but weaker
effect on sIL-6R release was observed in cul-
tures of normal B lymphocytes in the presence
of PMA. In a recent study, Mullberg et al.22
showed that the ligand binding subunit gp80 of
human IL-6R was shed by transfected COS-7
cells. The shedding was greatly increased by
exposing the cells to PMA. PMA treatment
induced protein kinase C (PKC) that regulated
shedding of sIL-6R.22 These data accord well
with our ￿ndings that treatment with PMA
markedly increased the levels of sIL-6R in
culture supernatants. The effect of PWM was
variable and not signi￿cant. A possible explana-
tion for the difference in effects between the
two stimulants could be due to the property of
PMA to promote mainly terminal differentiation
of B cells for which IL-6 is necessary23 and thus,
is utilized by the cells, while in the same time
sIL-6R is shed into the culture medium. PWM
stimulates mainly proliferation of B lymphocytes
which is probably less dependent on IL-6.24
Two types of possible functions of sIL-6R were
postulated: an antagonistic activity or an agonis-
tic mode of action. We did not attempt to de￿ne
what is the most likely possibility in our
experimental system.
No signi￿cant difference was observed be-
tween the levels of IL-6 and sIL-6R in the
supernatants from puri￿ed and nonpuri￿ed B-
CLL B cell cultures, thus indicating that the
main contribution was made by B lymphocytes.
However, a trend to increased levels of IL-6 in
cultures of not puri￿ed B-CLL B lymphocytes
might be due to additional secretion of IL-6 by
residual Tcells.
IL-6 was not detected in culture supernatants
of unstimulated or stimulated normal B lympho-
cytes. The difference between the results ob-
tained with B-CLLversus normal B lymphocytes
could be due to the fact that B-CLL B cells are
stimulated B cells and as such they secrete IL-6
into the culture medium. Reaction of IL-6 with
IL-6R upregulated by PMA, could result in
shedding of sIL-6R into the culture superna-
tants. This will occur to a far lesser extent with
normal B cells because the level of IL-6 in the
culture supernatants was much lower.
The levels of IL-6 in sera of normal subjects
was below the limit of detection (, 60 pg ml).
Surprisingly this was also the case with sera
from B-CLLpatients in spite of the high levels of
IL-6 detected in cultures of B-CLL B cells,
although the number of Bcells in the peripheral
blood of B-CLLpatients was from 20 to 60 times
higher than in normal subjects. A plausible
explanation for this discrepancy could be that
IL-6 is taken up and utilized by various cells in
the body while at the same time sIL-6R is
probably secreted into the blood possibly after
reaction with IL-6, thus allowing detection of
measurable quantities in the serum. It was
recently shown that sIL-6R in body ￿uids is
biologically active.25 Our ￿nding of direct corre-
lation between the levels of sIL-6R in the serum
and the number of circulating B-CLL B lympho-
cytes is consistent with the view that increase
in sIL-6Rlevels is driven by IL-6.
The small number of B-CLLpatients belonging
to the more advanced stages of Rai classi￿cation
3 and 4, does not allow any clear correlation
between the stages of B-CLL and the serum IL-6
and sIL-6Rlevels. However, B lymphocytes from
two cases with Rai stage 3 produced less than
5 ng/ml of IL-6 in cultures, whereas most cases
with Rai stage 4 produced more than 10 ng/ml.
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